Sculptor Capital’s Biotech Acquisition Company Warrant BIOTW Stock Holding History

Sculptor Capital’s Portfolio BIOTW Stock Details BIOTW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-150,000	Closed	-$9.32K	–	870
2022 Q4	$9.32K	Hold	150,000	–	–	﹤0.01%	684
2022 Q3	$8K	Hold	150,000	–	–	﹤0.01%	1003
2022 Q2	$10K	Hold	150,000	–	–	﹤0.01%	1098
2022 Q1	$35K	Hold	150,000	–	–	﹤0.01%	1129
2021 Q4	$94K	Hold	150,000	–	–	﹤0.01%	995
2021 Q3	$97K	Hold	150,000	–	–	﹤0.01%	846
2021 Q2	$130K	Hold	150,000	–	–	﹤0.01%	821
2021 Q1	$86K	Buy	+150,000	New	+$106K	﹤0.01%	641

Sculptor Capital's BIOTW Position: Q1 2023 in Review

Sculptor Capital sold out of Biotech Acquisition Company Warrant (BIOTW) in Q1 2023, closing a stake of 150,000 shares — an estimated $9.32K sold.

Sculptor Capital first reported a position in BIOTW in Q1 2021 and held it in 8 quarters. The position peaked at $130K in Q2 2021. 0 funds tracked by Wall St. Rank hold BIOTW as of Q1 2023.

Sculptor Capital reported no remaining Biotech Acquisition Company Warrant position as of Q1 2023 after selling out during the quarter.
Sculptor Capital sold 150,000 Biotech Acquisition Company Warrant shares in Q1 2023, an estimated $9.32K.
Sculptor Capital first reported a position in Biotech Acquisition Company Warrant in Q1 2021 and held it in 8 quarters.
Sculptor Capital's Biotech Acquisition Company Warrant position peaked at $130K in Q2 2021.
0 funds tracked by Wall St. Rank held Biotech Acquisition Company Warrant as of Q1 2023.

Based on Sculptor Capital's 13F filing for Q1 2023, filed 16 May 2023.